AI Drug Discovery Pipeline

The third gene-editing therapeutics name in a mandate that names computational discovery, not therapeutic modality bets. It was already trimmed twice — 10.01% to 8.96% on 09-15 and 8.09% to 4.46% on 09-26 — each time for redundant preclinical risk, and at 4.5% it had become a stub contributing correlation to BEAM and CRSP without conviction. Pre-revenue in-vivo CRISPR, only +1.6% over entry, no catalyst in the tape. Closing it consolidates editing exposure into CRSP, the only one of the three that has crossed into commercial, and BEAM, the more differentiated platform, and recycles the proceeds into the underweight ML discovery platform sleeve.

The FDA clearance for the heart-valve AI tool on 09-28 is real and keeps the thesis alive, which is why this is a trim and not an exit. But three separate insider sales printed inside one week — diagnostics CEO 10,281 shares at $85 on 09-29, EVP Polovin $221k and CAO Bartolucci $530k on 09-28 — and the stock now trades $76.50, roughly 10% below where those sellers transacted and -6.59% today. Insiders distributing into a bid that then broke is a momentum breakdown layered on the governance concern the last two runs already trimmed for. An 8% core stays for the multimodal oncology data network.

Substitute instrument for the mandate's dead EXAI listing, which is unbuyable — SnapTrade cannot resolve it and the US listing ended 2024-11-20, so an order could not be filled at any size. Absci is the closest listed analogue to that slot: generative AI de novo antibody design, the AI-first discovery platform model the 40% ML sleeve is built around. $1.85B cap, LifeSci Capital maintains a $16 target against $10.75 spot and the stock rose 6.1% on 09-29. Guggenheim's reiterated rating on the endometriosis trial delay is a timing slip on one program, not a platform invalidation, and $1.6M TTM revenue is partnership-deal lumpiness on a pre-commercial platform. Sized at a 5% starter weight, deliberately below ABCL and SDGR, because the Phase 2 plan is still taking shape.

Clinical AI & Trial Optimization is the mandate's 25% sleeve and runs underweight after trimming TEM. Veeva is the system of record for clinical trial execution with real, high-margin recurring revenue — the right place to carry sleeve weight when the sleeve's other anchor has an active governance overhang. Down 1.23% today with the tape, not on news.

Simulations Plus is the purest listed expression of model-informed drug development and biosimulation, opened as a 4% stub on 09-24. Up 0.33% today against XBI at -2.01% — genuine relative strength in a risk-off biotech tape. Sizing it to a real 5.5% weight fills the clinical sleeve without adding a fourth correlated name.

JPMorgan initiated coverage at Overweight with a $17 price target on 2026-09-30 — the first major-bank initiation on the name and 22% above today's $13.91. The 4.66% drop today tracks the XBI tape at -2.01% rather than any company news, so this adds to a strengthening thesis at a better price. ABCL is the ML platform sleeve's strongest holding at +25.1% over entry, and the sleeve itself is underweight the mandate's 40% target.